Herceptin filed in US for HER2-positive stomach cancer
This article was originally published in Scrip
Executive Summary
Genentech (Roche) has filed for supplemental US FDA approval for its HER2-targeted drug Herceptin (trastuzumab) to treat advanced, HER2-positive gastric cancer, including gastroesophageal junction cancer.